Equities analysts predict that Inovio Pharmaceuticals Inc (NASDAQ:INO) will announce earnings per share (EPS) of ($0.29) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Inovio Pharmaceuticals’ earnings, with estimates ranging from ($0.33) to ($0.24). Inovio Pharmaceuticals reported earnings of ($0.36) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 19.4%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Inovio Pharmaceuticals will report full year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.18) to ($1.03). For the next fiscal year, analysts anticipate that the firm will report earnings of ($1.26) per share, with EPS estimates ranging from ($1.47) to ($1.04). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Inovio Pharmaceuticals.
INO has been the topic of several recent research reports. HC Wainwright set a $13.00 price objective on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, January 3rd. ValuEngine cut Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, November 9th. Royal Bank of Canada began coverage on Inovio Pharmaceuticals in a research report on Wednesday, October 18th. They set an “outperform” rating and a $11.00 price target on the stock. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, BidaskClub cut Inovio Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, February 3rd. Two research analysts have rated the stock with a sell rating, three have given a hold rating and eight have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $19.16.
Several hedge funds have recently bought and sold shares of INO. Schwab Charles Investment Management Inc. increased its position in shares of Inovio Pharmaceuticals by 9.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 334,017 shares of the biopharmaceutical company’s stock worth $2,619,000 after purchasing an additional 28,173 shares during the last quarter. Alliancebernstein L.P. boosted its stake in Inovio Pharmaceuticals by 23.9% in the second quarter. Alliancebernstein L.P. now owns 95,500 shares of the biopharmaceutical company’s stock worth $749,000 after buying an additional 18,400 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in Inovio Pharmaceuticals by 5.0% in the second quarter. PNC Financial Services Group Inc. now owns 21,000 shares of the biopharmaceutical company’s stock worth $164,000 after buying an additional 1,000 shares in the last quarter. UBS Asset Management Americas Inc. boosted its stake in Inovio Pharmaceuticals by 0.4% in the second quarter. UBS Asset Management Americas Inc. now owns 25,710 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 92 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Inovio Pharmaceuticals by 2.8% in the second quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after buying an additional 24,366 shares in the last quarter. Institutional investors own 32.04% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This article was posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/brokerages-anticipate-inovio-pharmaceuticals-inc-ino-to-announce-0-29-eps.html.
About Inovio Pharmaceuticals
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inovio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.